MediciNova gains approval to present abstract on ALS therapy MN-166
Category: #Health  By Pankaj Singh  Date: 2019-07-31
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

MediciNova gains approval to present abstract on ALS therapy MN-166

The company CMO, Kazuko Matsuda will present the abstract titled “Interaction (nonuniformity) of ALS Progression and the Efficacy of MN-166 (ibudilast)” at the 30th International Symposium.

MediciNova, Inc., a biopharmaceutical organization focused on developing small-molecule therapeutics for the treatment of diseases that lack clinical cure, recently announced that an abstract concerning its completed clinical trial of MN-166 (ibudilast) in ALS has been approved for presentation at the 30th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND), scheduled in Perth, Australia. 

Speaking on the move, Dr. Yuichi Iwaki, President and Chief Executive Officer, MediciNova, said that the company is delighted to present its research on ALS at the 30th International Symposium on ALS/MND. He said that their firm will use this opportunity to share its study and results with all the ALS/MND researchers, patients and clinicians who initially laid the foundation of design and implementation of its upcoming ALS trial.  

Reportedly, the pilot was a double-blind, randomized, placebo-controlled study which involved six-month treatment period accompanied by a six-month open-label extension. In collaboration with Carolinas Neuromuscular/ALS-MDA Center’s Director, Dr. Benjamin Rix Brooks, MediciNova offered patients a dose of 60 mg of MN-166 per day in both early and last stage of ALS.

For the record, amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that damages nerve cells in the spinal cord and the brain. The nerves lose the ability to prompt specific muscles, which makes the muscles weak. The condition affects voluntary movement of patients which results to complete paralysis in the later stages. Generally, an ALS patient’s life expectancy lasts between 2-5 years.

However, MN-166 (ibudilast)'s neuroprotective and anti-neuroinflammatory actions provide the rationale for treatment of ALS, progressive MS (multiple sclerosis) and other neurological diseases like glioblastoma (GBM), and substance addiction/abuse. These actions have also been demonstrated in preclinical and clinical studies, cite reports.

Source Credit: https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-4



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Matterport announces partnership with Apex to digitize built world

Matterport announces partnership with Apex to digitize built world

By Pankaj Singh

Matterport, Inc., a 3D media platform developer, has recently announced a partnership with Apex, a consulting, engineering, and field services firm. This partnership deal has been entered with an objective to allow ret...

Stop & Shop collaborates with Volta Charging to offer EV charging

Stop & Shop collaborates with Volta Charging to offer EV charging

By Pankaj Singh

Stop & Shop has reportedly partnered with Volta Industries Inc. to install five electric vehicle charging stations across its Northeast stores fleet.

These stations will enable ...

CPSI announces a licensing partnership with Medicomp Systems

CPSI announces a licensing partnership with Medicomp Systems

By Pankaj Singh

CPSI Inc., a healthcare solution provider, has reportedly announced a licensing partnership with Medicomp Systems, a company that produces solutions for relevant, actionable, and usable medical data.